Interstitial Lung Disease Market Analysis: Epidemiology, Trends, and Foreca

DelveInsight's comprehensive report on "Interstitial Lung Disease Market Insights, Epidemiology and Market Forecast - 2032" delivers extensive understanding of Interstitial Lung Disease, encompassing historical and projected epidemiology alongside market dynamics in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Unlock key insights into the Interstitial Lung Disease Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Interstitial Lung Disease Market Size

Key Highlights from the Market Analysis

• On 10 November 2025, GB002 Inc. revealed a Phase 3 investigation structured as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The PCP's primary objective is to assess seralutinib's effect on enhancing exercise capacity in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease. The LTE's primary objective is to evaluate seralutinib's long-term safety and tolerability profile.

• On 10 November 2025, Vicore Pharma AB initiated a clinical trial that will enroll participants receiving stable licensed IPF therapy or those currently untreated with licensed IPF therapy. The latter category encompasses participants intolerant or non-responsive to licensed IPF therapies, participants ineligible for these therapies, and participants who have voluntarily opted out of licensed IPF therapy after receiving comprehensive information regarding potential benefits and risks. Due to potential drug-drug interaction (DDI) risks, concurrent treatment with pirfenidone is prohibited in this trial. Participants not receiving antifibrotic therapy at study initiation may commence such treatment during the investigation.

• The prevalence of ILD was documented at approximately 97.9 cases per 100,000 individuals in France.

• Observations revealed that sarcoidosis was the most frequently reported ILD in Italy, representing approximately 33.7% of cases, followed by IPF at approximately 27.4%. Combined, these two conditions accounted for over 60% of ILD cases, while hypersensitivity pneumonitis constituted approximately 2.9% of cases.

• In Spain, IPF emerged as the most prevalent ILD subtype, comprising approximately 38.6% of cases, followed by sarcoidosis at 14.9%, CTD-ILD at 10%, and hypersensitivity pneumonitis at 6.6%. Approximately 5% of cases were categorized as unclassifiable. Within the CTD-ILD cohort, rheumatoid arthritis represented the most common etiology.

• The prevalence of IPF in Japan was documented at nearly 27 cases per 100,000 population, with higher prevalence rates observed in males compared to females.

• Key pharmaceutical developers include R-Pharm International, LLC, Boehringer Ingelheim, GlaxoSmithKline, Insmed Incorporated, United Therapeutics, Liquidia Technologies, Inc., Bristol-Myers Squibb, aTyr Pharma, Inc., AstraZeneca, and others.

• Notable investigational therapies comprise BI 1015550, Nintedanib 150 MG [Ofev], Benralizumab, Imlifidase, Pirfenidone Capsules, and additional candidates.

Stay ahead in the competitive landscape of the Interstitial Lung Disease Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Interstitial Lung Disease Treatment Market Size

Epidemiological Segmentation in the 7MM

• Total Interstitial Lung Disease Prevalent Cases

• Total Interstitial Lung Disease Diagnosed Prevalent Cases

• Interstitial Lung Disease Gender-specific Diagnosed Prevalent Cases

• Interstitial Lung Disease Disease-specific Diagnosed Prevalent Cases

• Interstitial Lung Disease Treated Cases

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ Interstitial Lung Disease Prevalence

Market Intelligence

Therapeutic management of interstitial lung diseases (ILDs) is tailored according to the specific classification and severity level, emphasizing symptom relief and disease progression deceleration. Considering the frequently irreversible nature of pulmonary damage from ILDs, a holistic, multidisciplinary therapeutic approach is imperative. Pharmacological interventions constitute the cornerstone of ILD management. Corticosteroids are routinely prescribed to mitigate inflammatory processes, particularly in conditions such as bronchiolitis obliterans organizing pneumonia (BOOP) and hypersensitivity pneumonitis (HP), which typically demonstrate rapid responsiveness to steroid therapy. In cases demonstrating corticosteroid resistance, investigational immunosuppressive therapeutic approaches may be explored. Oxygen supplementation is critical for patients presenting with hypoxemia (oxygen saturation below 88%), as it optimizes respiratory function and minimizes complications linked to reduced blood oxygen concentrations. Furthermore, pulmonary rehabilitation programs can enhance lung operational efficiency, increase physical stamina, and deliver emotional support, thereby substantially improving patients' quality of life.

Emerging Therapeutic Assessment

• Nerandomilast (BI 1015550): Boehringer Ingelheim

• Efzofitimod (ATYR 1923): aTyr Pharma

• BMS-986278: Bristol Myers Squibb

Discover the future of Interstitial Lung Disease Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Interstitial Lung Disease Market Drivers and Barriers

Market Forecast Outlook

The Interstitial Lung Disease Market is projected to experience substantial expansion, driven by rising incidence rates of various interstitial lung disease types, including idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and sarcoidosis. Enhanced awareness and diagnostic technological advancements are facilitating earlier detection and more effective Interstitial Lung Disease management, thereby contributing to market growth.

Report Scope

• Geographic Coverage: Global

• Study Period: 2019-2032

• Featured Companies: R-Pharm International, LLC, Boehringer Ingelheim, GlaxoSmithKline, Insmed Incorporated, United Therapeutics, Liquidia Technologies, Inc., Bristol-Myers Squibb, aTyr Pharma, Inc., AstraZeneca, and others

• Pipeline Therapies: BI 1015550, Nintedanib 150 MG [Ofev], Benralizumab, Imlifidase, Pirfenidone Capsules, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Additional Coverage: Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Interstitial Lung Disease Market Access and Reimbursement

Explore the dynamics of the Interstitial Lung Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Interstitial Lung Disease Ongoing Clinical Trials Analysis

Table of Contents

1. Key Insights

2. Executive Summary of Interstitial Lung Disease

3. Competitive Intelligence Analysis for Interstitial Lung Disease

4. Interstitial Lung Disease: Market Overview at a Glance

5. Interstitial Lung Disease: Disease Background and Overview

6. Patient Journey

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Interstitial Lung Disease Unmet Needs

10. Key Endpoints of Interstitial Lung Disease Treatment

11. Interstitial Lung Disease Marketed Products

12. Interstitial Lung Disease Emerging Therapies

13. Interstitial Lung Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Interstitial Lung Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com